Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 38,509

Document Document Title
WO/2021/070150A1
The present invention relates to an inhalable composition comprising a therapeutically effective dosage amount of compound (I), 2-{4-[(2S)-1,1-difluoro-2-hydroxypropyl]phenyl}-N-{4-[3-(2-e thylphenyl) pyrazine-2-yl]phenyl}acetamide or a ...  
WO/2021/069721A1
Compounds (1-2) as modulators of Activating Transcription Factor 6 (ATF6) are provided. The compounds may find use as therapeutic agents for the treatment of diseases or disorders mediated by ATF6 and may find particular use in the treat...  
WO/2021/070090A1
Provided herein are compounds according to Formula (I) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R5, and R7 are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formul...  
WO/2021/002484A9
The present invention provides a sulfone derivative that is useful as a herbicide, and an industrially preferable production method for an intermediate of said derivative. Provided is a production method for a compound of formula (4), th...  
WO/2021/070957A1
Provided are a compound represented by formula (I) or a pharmaceutically acceptable salt thereof, and a medical composition which contains the same and is used to treat or prevent cognitive function diseases or disorders. [In the formula...  
WO/2021/068820A1
Disclosed in the present invention are an alkene-containing carboxylate compound and use of an agriculturally acceptable salt thereof as a herbicide. Said compound is as represented by general formula (I). The definition of the substitue...  
WO/2021/068815A1
Disclosed in the present invention are a carboxylic acid ester compound and an application thereof, the structure of the compound being shown in general formula I, and the definition of each substituent in general formula I being provide...  
WO/2021/068816A1
Disclosed are an alkene-containing amide compound and the use of an agriculturally acceptable salt thereof as a herbicide. The compound is as represented by general formula (I): the substituents in general formula I are defined in the de...  
WO/2021/069701A1
Compounds (I) as modulators of Activating Transcription Factor 6 (ATF6) are provided. The compounds may find use as therapeutic agents for the treatment of diseases or disorders mediated by ATF6 and may find particular use in the treatme...  
WO/2021/072300A1
Disclosed herein are phospholipid ether (PLE) molecules. Further provided are phospholipid-flavagline conjugates. The phospholipid-flavagline conjugate may include a PLE conjugated to a flavagline via a linker. Further provided herein ar...  
WO/2021/068953A1
The present invention belongs to the field of medicinal chemistry and relates to a class of substituted tricyclic compounds as PRMT5 inhibitors and the use thereof. Specifically, the present invention provides a compound represented by f...  
WO/2021/067805A1
This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that inhibit (e.g., antagonize) Stimulator of Interferon Genes...  
WO/2021/064677A1
Compounds of Formula I, including pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth: Formula I.  
WO/2021/065980A1
Provided is a BET degrader. A BET degrader including a compound represented by formula (I) or a pharmaceutically acceptable salt thereof is used. (In the formula, L1 and L2 are the same or different and represent a low molecular ligand f...  
WO/2021/066578A1
The present invention relates to a compound derivative bearing a 6-7 bicyclic ring and a use thereof. The compound according to the present invention acts as a protein arginine methyltransferases 5 (PRMT5) inhibitor and thus can be advan...  
WO/2021/067215A1
The present disclosure provides compounds represented by Formula (la): and the pharmaceutically acceptable salts thereof, wherein R1a, R1b, R1c, R2, R3, L, M and G are as defined as set forth in the specification. The present disclosure ...  
WO/2021/064142A1
The present invention relates to a compound of formula (I), optionally in the form of a pharmaceutically acceptable salt, solvate, cocrystal, tautomer, racemate, enantiomer, or diastereomer or mixture thereof : formula (I) and to pharmac...  
WO/2021/063967A1
The present invention relates to a compound of the formula (I) wherein Ar represents a phenyl or a 6-membered heteroaryl group, R1 and R2 represent independently a hydrogen atom or a deuterium atom, R3 represents (1) a -COR4 group, (2) a...  
WO/2021/066559A1
N-(1H-imidazol-2-yl)benzamide compound of formula (I), or a pharmaceutically acceptable salt, a prodrug, a solvate, or a stereoisomer thereof which is a novel compound exhibiting excellent inhibitory activity against IRAK-4, can be used ...  
WO/2021/067657A1
Disclosed are compounds of Formula (I) or salts thereof, wherein R1, R2, R3, R4, and R5 are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, 8, or 9, and pharmace...  
WO/2021/063852A1
The present invention provides novel compounds having the general formula: wherein R1 to R4, L1, L2 and X are as described herein, compositions including the compounds and methods of using the compounds.  
WO/2021/062557A1
This disclosure relates generally to cannabinoid derivatives having the formula (I), wherein R4 is hydrogen, -C(Q1)N(R4a)(R4b) or -C(R4J)(R4k)N(R4e)C(0)R4f, R6 is hydrogen, -C(Q2)N(R6a)(R6b) or -C(R6J)(R6k)N(R6e)C(0)R6f, provided that R6...  
WO/2021/067801A1
This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or prodrug, and/or tautomer, and/or drug combination of the compound) that inhibit (e.g., antagoniz...  
WO/2021/059220A1
The present invention relates to a process for the synthesis of 5-(4-((2S,5S)-5-(4-chlorobenzyl)- 2-methylmorpholino)piperidin-1-yl)-1H-1,2,4-triazol-3-amine in two hydrated crystalline forms and in one anhydrous crystalline form. The pr...  
WO/2021/057890A1
A class of compounds that have a pyrazine structure, specifically disclosed is a compound represented by formula (VII), isomers or pharmaceutically acceptable salts thereof, and an application thereof in the preparation of CRAC inhibitors.  
WO/2021/057994A1
Provided in the present invention are a pyrazole compound and a use thereof, wherein the structure of the compound is (I). The compound has an excellent activity of inhibiting the hepatitis B virus, and the compound of the present invent...  
WO/2021/057785A1
Disclosed is a compound represented by formula I, a stereoisomer, racemate, tautomer, isotopic label, prodrug thereof or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising same, a preparation method t...  
WO/2021/062189A1
lsoxazole-3-carboxam ide derivatives and their use in treating viral infections and diseases, such as diseases caused by viruses of the Picornaviridae family of viruses (e.g., rhinoviruses, enteroviruses, and coxsackieviruses) is describ...  
WO/2021/059136A1
Compounds of the general formula (I), or a pharmaceutically acceptable salt thereof, processes for the preparation of these compounds, compositions containing these compounds, and the uses of these compounds.  
WO/2021/060281A1
The purpose of the present invention is to provide a novel compound which has a prostaglandin E2 (PGE2) receptor EP2/EP4 dual antagonizing effect and is useful as: a preventive or therapeutic agent for a disease selected from cancer, pai...  
WO/2021/057915A1
An EP300/CBP inhibitor, specifically provided is a compound as shown in formula I, or a deuterated product thereof, or a salt thereof, or a conformational isomer thereof, or a crystal form thereof, or a solvate thereof. The compound is h...  
WO/2021/060567A1
The present invention provides a heterocyclic compound having a HDAC6 inhibitory action, which is useful for the treatment of central nervous system diseases including neurodegenerative diseases, and the like, and a medicament comprising...  
WO/2021/055612A1
The invention provides substituted imidazole carboxamides and related compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat a medical disorder, e.g., cancer, lysos...  
WO/2021/053110A1
Compounds of the formula (I), wherein the substituents are as defined in claim 1. Furthermore, the present invention relates to agrochemical compositions which comprise compounds of formula (I), to preparation of these compositions, and ...  
WO/2021/053161A1
Compounds of formula (I), wherein the substituents are as defined in claim 1, and the agrochemically acceptable salts, stereoisomers, enantiomers, tautomers and N-oxides of those compounds, can be used as insecticides.  
WO/2021/055627A1
The invention provides substituted N-heterocyclic carboxamides and related compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat a medical disorder, e.g., cancer, ...  
WO/2021/055376A1
The disclosure herein provides compounds and pharmaceutical compositions for the modulation of IL-17A useful for the treatment of inflammatory conditions, such as psoriasis.  
WO/2021/053555A1
Described herein are glue degrader compounds, their various targets, their preparation, pharmaceutical compositions comprising them, and their use in the treatment or prevention of conditions, diseases, and disorders mediated by various ...  
WO/2021/048200A1
The present invention relates to compounds of formula (I), (I), wherein R1, R2 and R3 are as described herein, and their pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and m...  
WO/2021/049840A1
The present specification relates to a heterocyclic compound and an organic light-emitting device comprising same.  
WO/2021/047547A1
The present invention provides a novel tricyclic aromatic heterocyclic compound, a preparation method therefor, a pharmaceutical composition and an application thereof. Specifically, the present invention provides a compound as represent...  
WO/2021/047674A1
A compound represented by formula (III) or a pharmaceutically acceptable salt thereof, and disclosed is an application thereof in the preparation of a medication for treating diseases related to a CRBN receptor.  
WO/2021/050915A1
The present invention relates to compounds that inhibit Protein Arginine N-Methyl Transferase 5 (PRMT5) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods ...  
WO/2021/050721A1
Provided herein are compounds, pharmaceutical compositions including such compounds, and methods of using such compounds to treat diseases or disorders associated with MDM2 activity.  
WO/2021/050583A1
Embodiments of the disclosure include methods and compositions for treating neurological disorders by stimulating regenerative and anti-inflammatory activity of fibroblasts. In specific embodiments, fibroblasts are administered to an ind...  
WO/2021/048567A1
The present invention relates to compounds of Formula (I) or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, optical isomer, N-oxide, and/or prodrug thereof. The present invention also relates to pharmaceutical compositio...  
WO/2021/047553A1
An aromatic heterocyclic compound having a tricyclic structure, and a preparation method therefor and application thereof, and in particular, a compound as shown in formula I, or an optical isomer, a hydrate, a solvate, or a pharmaceutic...  
WO/2021/049843A1
The present specification relates to a compound of chemical formula 1 and an organic light emitting device comprising same.  
WO/2021/047677A1
Provided are an IRAK4 kinase inhibitor, and preparation thereof and use thereof, specifically provided are a compound represented by formula (I), a stereoisomer thereof, a geometric isomer thereof, a tautomer thereof, a pharmaceutically ...  
WO/2021/049595A1
Pests still cause major damage, and pests occur that resistant to existing pesticides, so the present invention addresses the problem in crop production, including agriculture and horticulture, of developing and providing a novel agricul...  

Matches 1 - 50 out of 38,509